Follow us on Twitter
twitter icon@FreshPatents


Histidine patents

      

This page is updated frequently with new Histidine-related patent applications.




 Raman spectroscopy for bioprocess operations patent thumbnailRaman spectroscopy for bioprocess operations
A method of characterizing a multi-component mixture for use in a bioprocess operation that includes providing a multi-component mixture standard with pre-determined amounts of known components; performing a raman spectroscopy analysis on the multi-component mixture standard; providing a multi-component test mixture from the bioprocess operation; performing a raman spectroscopy analysis on the multi-component test mixture; and comparing the analysis of the multi-component mixture standard and the multi-component test mixture to characterize the multi-component test mixture. In one embodiment, the multi-component mixture standard and the multi-component test mixture both comprise one or more of, at least two, at least three of, or each of, a polysaccharide (e.g.
Abbvie, Inc.


 Biosensors patent thumbnailBiosensors
The invention relates to biosensors, more particularly to protein biosensors and their use to indicate the formation of denaturing ice crystals in samples. The invention includes the use of a protein as a biosensor to indicate denaturing ice-crystal formation in a sample, wherein the protein is denaturable by denaturing ice crystals from a non-denatured state to a denatured state and wherein said non-denatured and denatured states are associated with detectably different indications, e.g.
Protein Technologies Limited


 Improved b-fructofuranosidase patent thumbnailImproved b-fructofuranosidase
[solution] an improved β-fructofuranosidase comprising an amino acid sequence which is produced by introducing an amino acid mutation into an amino acid sequence for a β-fructofuranosidase having 60% or higher identity to the amino acid sequence for wild-type β-fructofuranosidase which is represented by seq id no: 2, wherein the amino acid mutation is such a mutation that, when amino acid sequence alignment is performed, a histidine (h) residue corresponding to the position 395 as numbered from the n-terminal of the amino acid sequence for the wild-type β fructofuranosidase which is represented by seq id no: 2 can be replaced by an arginine (r) residue or a lysine (k) residue.. .

 Gene encoding a mutant protein providing a decorative flowering phenotype in plants patent thumbnailGene encoding a mutant protein providing a decorative flowering phenotype in plants
The present invention relates to proteins capable of providing a decorative flowering phenotype in plants and especially in plants belonging to the kalanchoe genus. The present invention also relates to nucleic acid sequences, or cdna sequences, and genes encoding the present proteins.
Fides Bv


 Histidine engineered light chain antibodies and genetically modified non-human animals for generating same patent thumbnailHistidine engineered light chain antibodies and genetically modified non-human animals for generating same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
Regeneron Pharmaceuticals, Inc.


 Phosphohistidine mimetics and antibodies to same patent thumbnailPhosphohistidine mimetics and antibodies to same
Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs. The invention is based in part on new phis analogs that are chemically stable and which have been used as haptens and immunogens to generate specific anti-phis antibodies that bind with high affinity and specificity..
The Trustees Of Princeton University


  patent thumbnail
Methods of ameliorating, treating, or reducing post-dialysis washout or hangover comprising administering, near the end of or subsequent to a dialysis session, one or more or a group of amino acids and/or their hydroxy or keto analogs. The group of amino acids may be one or more members selected from the group consisting of histidine, alanine, isoleucine, arginine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, pyrrolysine, proline, selenocysteine, serine, and tyrosine, or their keto or hydroxy analogs and mixtures thereof..
Calwood Nutritionals, Llc


 Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same patent thumbnailPolypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
The present description relates to synthetic peptides useful for increasing the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells. More specifically, the present description relates to synthetic peptides and polypeptide-based shuttle agents comprising an endosome leakage domain (eld) operably linked to a cell penetrating domain (cpd), or an eld operably linked to a histidine-rich domain and a cpd.
Feldan Bio Inc.


 Food containing histidine and use thereof patent thumbnailFood containing histidine and use thereof
Ingesting a food etc. Which is in a unit package form per meal and contains, in the unit, not less than 0.3 g of histidine as an ingestion amount per meal is effective for improving mental energy and biorhythm..
Ajinomoto Co., Inc.


 Stabilized factor ix formulations containing trehalose patent thumbnailStabilized factor ix formulations containing trehalose
Methods of preparing lyophilized preparations of factor ix which preserve more than 90% of the calcium binding property of factor ix are disclosed. Factor ix formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° c./60% relative humidity (rh) and 40° c./75% rh relative to factor ix formulated without trehalose.
Cnj Holdings, Inc.


Anti-fatigue composition

Compositions and foods which contain (1) histidine and (2) vitamin b6 and/or carnosine are useful for treating, improving, and recovering from fatigue.. .
Ajinomoto Co., Inc.

Cationic oligonucleotides, automated methods for preparing same and their uses

The invention relates to oligonucleotide-oligocation molecules aibjh that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties ai and oligocations moieties bj, wherein .ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide a is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (lna) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2′-fluoro, 2′-o-alkyl, or a marker group such as a fluorescent agent, .bj is a j-mer organic oligocation moiety, with j=1 to 50, where b is selected from the group comprising .—hpo3—r1—(x—r2n)n1—x—r3—o—, where r1, r2n and r3, identical or different, are lower alkylene, x is nh or nc(nh2)2, n varies from 1 to 5 and n1=2 to 20, .—hpo3—r4—ch(r5x1)—r6—o—, where r4 is lower alkylene, r5 and r6, identical or different, are lower alkylene and x1 is putrescine, spermidine or spermine residue, .—hpo3—r7-(aa)n2-r8—o—, where r7 is lower alkylene and r8 is lower alkylene, serine, a natural aminoalcohol, (aa)n2 is a peptide containing natural aminoacids with cationic side chains, such as arginine, lysine, ornithine, -histidine, diaminopropionic acid and n2=2 to 20.. .
Polyplus Transfection

Antibody-drug conjugate lyophilised formulation

Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (adcs), such as anti-tissue factor adcs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-tf adc based on an auristatin derivative or other similarly hydrophobic drug.
Genmab A/s

Stable formulations of polypeptides and uses thereof

Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation.
Ablynx N.v.

Food compositions containing all essential nutrients

A food composition that includes at least the following essential nutrients: water, choline, omega-3, omega-6, leucine, isoleucine, lysine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, threonine, valine, histidine, arginine; vitamin a; vitamin c; calcium; iron; vitamin d; vitamin e; vitamin k; thiamin; riboflavin; niacin; vitamin b6; folate; vitamin b12; biotin; pantothenic acid; phosphorus; iodine; magnesium; zinc; selenium; copper; manganese; chromium; molybdenum; and chloride.. .
Nutrient Foods, Llc

Method for producing amino acids using bacterium of the enterobacteriaceae family

A method for producing an l-amino acid is described, for example, l-phenylalanine and l-histidine, by fermentation using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified by attaching a dna fragment able to be transcribed encoding the peptide represented in seq id no: 2, or a variant thereof, particularly a portion of the ssra gene, to the 3′-end of gene encoding for the bacterial enzyme, which influences on the l-amino acid biosynthesis, such as chorismate mutase/prephenate dehydrogenase or phosphoglucose isomerase.. .
Ajinomoto Co., Inc.

Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds

Provided herein are nα,nα,nα-trialkyl histidine derivative compounds and methods of their preparation. Also provided are methods of their use for preparing useful compounds such as ergothioneine..
Mironova Innovations Llc

Interfering rna delivery system and uses thereof

The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
Arrowhead Pharmaceuticals Inc.

Human trypsinogen with reduced autoactivation and its use in an immunoassay

The present invention relates to a polypeptide consisting of or comprising a variant of human trypsinogen-1, comprising the substitutions: amino acid residue e64 is replaced with an amino acid residue comprising a positively charged side chain, amino acid residue k123 is replaced with an amino acid residue comprising an aliphatic side chain and amino acid residues y139 and d147 are replaced with a glutamine or asparagine residue, and wherein said variant is further characterized in that: an amino acid residue selected from e16, e17 and e142 is replaced with an amino acid residue comprising an aliphatic side chain, and/or amino acid residue n18 is replaced with a histidine residue, and/or amino acid residue r107 is replaced with a lysine residue, and/or amino acid residue d138 is replaced with an amino acid residue comprising a positively charged side chain, and wherein said variant is cleavable into a polypeptide having a native-like enzymatic activity when compared to human trypsin-1.. .
Universitat Leipzig

Lentiviral vectors having a mutated integrase protein and uses thereof

The present invention relates to a lentiviral vector wherein the expressed integrase protein comprises at least one point mutation consisting of the substitution of the aspartic acid residue at position 167 by an amino acid selected from the group consisting of histidine, arginine and lysine.. .
Universite Paris Sud

Mice that produce antigen-binding proteins with ph-dependent binding characteristics

Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.

Phosphohistidine and phosphotyrosine analogues

The invention relates to phosphohistidine analogues. The invention also relates to antibodies that specifically bind to the analogues and methods of generating said antibodies.
University Of Sheffield

Methionyl trna synthetase for biosynthesis of photomethionine-labeled protein and preparing photoactive protein g variant using same

Provided is a methionyl trna synthase (mrs) for the biosynthesis of a photomethionine-labeled protein and a method for preparing a photoactivatable protein g variant using same and, more particularly, to an mrs variant in which alanine at the position of 12th is substituted with glycine, leucine at the position of 13th by serine, tyrosine at the position of 260th by phenylalanine, isoleucine at the position of 297th by valine, and histidine at the position of 301st by leucine from the n-terminal of the amino acid sequence of a wild-type escherichia coli methionyl trna synthase. The mrs variant effectively confirms the biosynthesis of a photomethionine (pm)-labeled target protein and thus can be utilized for the biosynthesis of a pm-labeled target protein.
Korea Research Institute Of Bioscience And Biotechnology

Sowing unit and uses thereof

A sowing unit including water-absorbing material, an enclosure and a seed, wherein the water-absorbing material includes a hygroscopic negatively-charged material capable of binding a positively charged nutrient ion selected from nh4+, l-arginine, l-lysine and l-histidine; and optionally a nutrient including a positively charged nutrient ion selected from k+, nh4+, l-arginine, l-lysine and l-histidine. Methods and uses of the sowing unit are described..
Sveaskog Ab

Amino acid composition for use in the treatment of a pdd

The invention relates to the use of at least one amino acid, selected from the group of histidine, lysine, and threonine in the manufacture of a composition for use in the treatment of a pervasive development disorder, a neurogenetic syndrome associated with a pervasive development disorder or a symptom of a pervasive development disorder. The invention further relates to a food product comprising histidine, lysine, and/or threonine, to a supplement comprising histidine, lysine, and/or threonine and to a kit of parts comprising histidine, lysine, and/or threonine..

Method of inhibiting copper deposition on hair

A method of inhibiting copper deposition on hair and facilitating the removal of copper deposited on hair including applying to the hair a bleaching or oxidative dyeing composition comprising a chelant, rinsing the bleaching or oxidative dyeing composition, applying to the hair a rinse-off conditioner composition comprising histidine, rinsing the rinse-off conditioner composition from the hair, applying to the hair a shampoo composition having ethylenediamine-n,n′-disuccinic acid and/or histidine, rinsing the shampoo composition from the hair, applying to the hair a rinse-off conditioner composition comprising histidine, and rinsing the conditioner composition from the hair.. .

Subcutaneous anti-her2 antibody formulations and uses thereof

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody, such as e.g. Trastuzumab (herceptin™), pertuzumab or t-dm1, or a mixture of such antibody molecules for subcutaneous injection.
Genentech, Inc.

Insect metalloproteinase inhibitors

The polar amino acid position 39 of impiα is replaced either by the nonpolar amino acid valine or by the polar amino acids histidine or lysine.. .

Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland

Methods, compositions and apparatuses for facilitating regeneration

A polypeptide having at least 70% homology, in particular 80%, 90% or 95% homology to the polypeptide of seq id no 2 representing the wild-type of the protein insect metalloproteinase inhibitor impia and having at least one mutation at position 35, 36 and/or 39 of the amino acid sequence of impia and the polypeptide having an ic50 value to thermolysine of less than the ic50 value of impia wherein—the nonpolar amino acid isoleucine at position 35 of impiα is replaced either by a nonpolar amino acid selected from the group consisting of leucine, methionine and phenylalanine or by polar amino acid selected from the group consisting of cysteine, asparagine, glutamine, histidine, lysine and arginine; and/or—the nonpolar amino acid isoleucine at position 36 of impia is replaced either by a nonpolar amino acid selected from the group consisting of valine, phenylalanine and tryptophan or by polar amino acid selected from the group consisting of tyrosine, serine, threonine, asparagine, glutamine, histidine, lysine and arginine; and/or—the polar amino acid position 39 of impia is replaced either by the nonpolar amino acid valine or by the polar amino acids histidine or lysine.. .
Siwa Corporation

Therapeutic agent, treatment and predicting the severity of systemic inflammatory response syndrome (sirs), diseases caused or accompanied by neutrophil activation

The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (hrg) for the treatment of systemic inflammatory response syndrome (sirs), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (sirs), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (sirs), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject..
National University Corporation Okayama University

Heparin affinity tag and applications thereof

In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions.
The Board Of Trustees Of The University Of Arkansas

Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids

This invention relates to composition and method of preparation of aminomedix™ comprising of amifostine, at least one amino acid (arginine, lysine, histidine) with or without other pharmaceutically active compounds. The aminomedix™ composition can be applied for kidney protection during therapy using radiolabeled and non-radiolabeled compounds, contrast agents, chemotherapeutics, antibiotics and drugs showing nephrotoxic effect..
Aminomedix Inc.

Highly concentrated pharmaceutical formulations

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody, such as e.g. Rituximab, ocrelizumab, or humab<cd20>, or a mixture of such antibody molecules for subcutaneous injection.
Genentech, Inc.

Method for detection of protein comprising histidine-tag using immunochromatography

The present invention relates to a method for the detection of a protein including a histidine-tag using immunochromatography. The detection method of the present invention uses immunochromatography using the polymer particle fixed with the histidine-tag, wherein a histidine-tag specific antibody alone is used to detect a histidine-tag conjugated protein (recombinant protein) quickly without using a target protein specific antibody.
Daegu Gyeongbuk Institute Of Science And Technology

Factor ix polypeptide mutant, its uses and its production

Disclosed are a modified fix (factor ix) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified fix polypeptide; a nucleotide sequence coding for the modified fix polypeptide; and a method for producing the modified fix polypeptide.. .

Bile acid-basic amino acid conjugates and uses thereof

Compositions and methods for treating diseases or disorders associated with the metabolic syndrome using conjugates of bile acids with basic amino acids or a decarboxylated amino acid such as agmatine are provided. Further provided are bile acid-basic amino acid conjugates including chenodeoxycholic acid with an amino acid selected from arginine, lysine, histidine, ornithine or a decarboxylated amino acid such as agmatine..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Polymer composition and polymer material

A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group..
Industrial Technology Research Institute

Methods to inhibit infection during wound healing with topical compositions including amino acids

A method that inhibits infection during wound healing by topical application of a single composition, which contacts a wound for a period of time to initiate wound healing. The single composition may include a mixture of all or some of the amino acids including: histidine monohydrochloride monohydrate; isoleucine; leucine; lysine acetate; methionine; phenylalanine; threonine; tryptophan; valine; alanine; arginine acetate; aspartic acid; glutamine; glycine; proline; serine; and tyrosine, which may provide aqueous mixtures of a range of osmolarities or a powdered mixture of amino acids.

Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight..

Nitrile hydratase

Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
Mitsubishi Rayon Co., Ltd.

Process of making and using pharmaceutical formulations of antineoplastic agents

In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .
Merck Sharp & Dohme Corp.

Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life

Organ and tissue preservation solutions having improved formulations are comprised of two separate solutions. The first solution includes one or more salts, water, dissolved oxygen, lactobionic acid, mannitol, glutamic acid and histidine at a ph of at least 7, preferably from about 7.3 to about 8.3.
Somahlution, Llc

Histidine and/or histidine derivative for the treatment of inflammatory skin diseases

histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject.
The University Of Manchester

Nitrile hydratase

Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
Mitsubishi Rayon Co., Ltd.

Lyase enzymes, nucleic acids encoding them and methods for making and using them

This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
Basf Enzymes Llc

Dna aptamers binding the histidine tag and their application

A dna aptamer was obtained which has an affinity for his-tag, and contains a nucleotide sequence selected from seq id no. 1 and seq id no.
Uniwersytet Jagiellonski

Prodrugs with prolonged action

A prodrug derivative of a bioactive peptide (or polypeptide) is provided that exhibits prolonged half-life in serum and prolonged action in vivo, compared to the parent peptide or polypeptide. In some embodiments, the peptide is selected from the group consisting of glucagon, exendin-4, glp-1, glp-2, gip, vasoactive intestinal peptide (vip), pituitary adenylate cyclase-activating polypeptide 27 (pacap-27), peptide histidine methionine (phm), oxyntomodulin, secretin, osteocalcin, growth hormone releasing hormone, as well as analogs, derivatives and conjugates..
Indiana University Research And Technology Corporation

Methods and compositions for increasing the anaerobic working capacity in tissues

Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine..
Natural Alternatives International, Inc.



Histidine topics:
  • Amino Acid
  • Amino Acids
  • Genetically
  • Antibodies
  • Immunoglobulin
  • Polypeptide
  • Nucleic Acid
  • Pertuzumab
  • Trastuzumab
  • Mesoporous Silica
  • Hemoglobin
  • Specificity
  • Carrier Molecule
  • Blood Plasma
  • Recombinant


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0366

    file did exist - 2294

    1 - 1 - 51